Boisson, M.; AP-HP, Service de Rééducation et de Réadaptation de l’Appareil Locomoteur et des Pathologies du Rachis, Hôpitaux Universitaires Paris Centre - Groupe Hospitalier Cochin, Paris, 75014, France
Borderie, D.; Université de Paris, UFR Pharmacie, Sorbonne Paris Cité, Paris, 75006, France, AP-HP, Service de Diagnostic Biologique Automatisé, Hôpitaux Universitaires Paris Centre - Groupe Hospitalier Cochin, Paris, 75014, France, INSERM UMR 1124, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire, UFR Sciences Fondamentales et Biomédicales, Paris, 75006, France
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Teboul-Coré, S.; AP-HP, Service de Rééducation et de Réadaptation de l’Appareil Locomoteur et des Pathologies du Rachis, Hôpitaux Universitaires Paris Centre - Groupe Hospitalier Cochin, Paris, 75014, France
Lefèvre-Colau, M.-M.; AP-HP, Service de Rééducation et de Réadaptation de l’Appareil Locomoteur et des Pathologies du Rachis, Hôpitaux Universitaires Paris Centre - Groupe Hospitalier Cochin, Paris, 75014, France, Université de Paris, UFR Médecine, Sorbonne Paris Cité, Paris, 75006, France, INSERM UMR 1153, Centre de Recherche Épidémiologie et Statistique Paris Sorbonne Cité (CRESS), ECaMO Team, Paris, 75006, France, Institut Fédératif de Recherche sur le Handicap, Paris, 75013, France
Rannou, F.; AP-HP, Service de Rééducation et de Réadaptation de l’Appareil Locomoteur et des Pathologies du Rachis, Hôpitaux Universitaires Paris Centre - Groupe Hospitalier Cochin, Paris, 75014, France, INSERM UMR 1124, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire, UFR Sciences Fondamentales et Biomédicales, Paris, 75006, France, Université de Paris, UFR Médecine, Sorbonne Paris Cité, Paris, 75006, France
Nguyen, C.; AP-HP, Service de Rééducation et de Réadaptation de l’Appareil Locomoteur et des Pathologies du Rachis, Hôpitaux Universitaires Paris Centre - Groupe Hospitalier Cochin, Paris, 75014, France, INSERM UMR 1124, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire, UFR Sciences Fondamentales et Biomédicales, Paris, 75006, France, Université de Paris, UFR Médecine, Sorbonne Paris Cité, Paris, 75006, France
Language :
English
Title :
Serum biomarkers in people with chronic low back pain and Modic 1 changes: a case-control study
Disease, G. B. D., Injury, I. & Prevalence, C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211–1259 (2017).
Modic, M. T., Steinberg, P. M., Ross, J. S., Masaryk, T. J. & Carter, J. R. Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging. Radiology 166, 193–9 (1988).
Nguyen, C. et al. Assessment of ankylosing spondylitis criteria in patients with chronic low back pain and vertebral endplate Modic I signal changes. J Rheumatol 37, 2334–9 (2010).
Rannou, F. et al. High-sensitivity C-reactive protein in chronic low back pain with vertebral end-plate Modic signal changes. Arthritis Rheum 57, 1311–5 (2007).
Boisson, M., Lefèvre-Colau, M.-M., Rannou, F. & Nguyen, C. Active discopathy: a clinical reality. RMD Open 0, e000660 (2018).
Nguyen, C., Poiraudeau, S. & Rannou, F. From Modic 1 vertebral-endplate subchondral bone signal changes detected by MRI to the concept of ‘active discopathy’. Ann Rheum Dis 74, 1488–94 (2015).
Cao, P. et al. Intradiscal injection therapy for degenerative chronic discogenic low back pain with end plate Modic changes. Spine J 11, 100–6 (2011).
Nguyen, C. et al. Intradiscal Glucocorticoid Injection for Patients With Chronic Low Back Pain Associated With Active Discopathy: A Randomized Trial. Ann Intern Med 166, 547–556 (2017).
Sainoh, T. et al. Single Intradiscal Administration of the Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, for Patients with Discogenic Low Back Pain. Pain Med 17, 40–5 (2016).
Tang, P. et al. The NLRP3/Caspase-1/Interleukin-1β Axis Is Active in Human Lumbar Cartilaginous Endplate Degeneration. Clin Orthop Relat Res 474, 1818–26 (2016).
Belge Kurutas, E., Senoglu, M., Yuksel, K. Z., Unsal, V. & Altun, I. Oxidative/Nitrosative Stress in Patients With Modic Changes: Preliminary Controlled Study. Spine (Phila Pa 1976) 40, 1101–7 (2015).
Teboul-Coré, S. et al. Bone mineral density and bone remodeling markers in chronic low back pain patients with active discopathy: A case-control exploratory study. PLoS One 13, e0196536 (2018).
von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453–7 (2007).
Reznick, A. Z. & Packer, L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 233, 357–63 (1994).
Hu, M. L. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 233, 380–5 (1994).
Witko-Sarsat, V. et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49, 1304–13 (1996).
Rannou, F. et al. Monolayer anulus fibrosus cell cultures in a mechanically active environment: local culture condition adaptations and cell phenotype study. J Lab Clin Med 136, 412–21 (2000).
Bai, B. & Li, Y. Combined detection of serum CTX-II and COMP concentrations in osteoarthritis model rabbits: an effective technique for early diagnosis and estimation of disease severity. J Orthop Surg Res 11, 149 (2016).
Henrotin, Y., Sanchez, C., Bay-Jensen, A. C. & Mobasheri, A. Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives. Ann Phys Rehabil Med 59, 145–8 (2016).
Roux, C. H. et al. MRI and serum biomarkers correlate with radiographic features in painful hand osteoarthritis. Clin Exp Rheumatol 34, 991–998 (2016).
Capossela, S., Pavlicek, D., Bertolo, A., Landmann, G. & Stoyanov, J. V. Unexpectedly decreased plasma cytokines in patients with chronic back pain. J Pain Res 11, 1191–1198 (2018).
Kleiner, G., Marcuzzi, A., Zanin, V., Monasta, L. & Zauli, G. Cytokine levels in the serum of healthy subjects. Mediators Inflamm 2013, 434010 (2013).
Baskol, M., Dolbun Seckin, K. & Baskol, G. Advanced oxidation protein products, total thiol levels and total oxidant/antioxidant status in patients with nash. Turk J Gastroenterol 25(Suppl 1), 32–7 (2014).
Mekrungruangwong, T., Seenak, P., Luangaram, S., Thongsri, T. & Kumphune, S. The serum protein carbonyl content level in relation to exercise stress test. Int J Health Allied Sci 1, 200–203 (2012).
Henrotin, Y. et al. Type II collagen peptides for measuring cartilage degradation. Biorheology 41, 543–7 (2004).
Burke, J. G. et al. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J Bone Joint Surg Br 84, 196–201 (2002).
Le Maître, C. L., Hoyland, J. A. & Freemont, A. J. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile. Arthritis Res Ther 9, R77 (2007).
Dimozi, A., Mavrogonatou, E., Sklirou, A. & Kletsas, D. Oxidative stress inhibits the proliferation, induces premature senescence and promotes a catabolic phenotype in human nucleus pulposus intervertebral disc cells. Eur Cell Mater 30, 89–102, discussion 103 (2015).
Richette, P. et al. A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis. J Rheumatol 35, 1650–4 (2008).